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The Epstein-Barr Virus (EBV) immediate-early protein BRLF1 is one of two transactivators which mediate
the switch from latent to lytic replication in EBV-infected cells. DNA viruses often modulate the function of
critical cell cycle proteins to maximize the efficiency of virus replication. Here we have examined the effect of
BRLF1 on cell cycle progression. A replication-deficient adenovirus expressing BRLF1 (AdBRLF1) was used
to infect normal human fibroblasts and various epithelial cell lines. BRLF1 expression induced S phase entry
in contact-inhibited fibroblasts and in the human osteosarcoma cell line U-2 OS. AdBRLF1 infection produced
a dramatic increase in the level of E2F1 but not E2F4. In contrast, the levels of Rb, p107, and p130 were
decreased in AdBRLF1-infected cells. Electrophoretic mobility shift assays confirmed an increased level of free
E2F1 in the AdBRLF1-infected human fibroblasts. Consistent with the previously described effect of E2F1,
AdBRLF1-infected fibroblasts had increased levels of p53 and p21 and died by apoptosis. BRLF1-induced
activation of E2F1 may be required for efficient EBV lytic replication, since at least one critical viral replication
gene (the viral DNA polymerase) is activated by E2F (C. Liu, N. D. Sista, and J. S. Pagano, J. Virol.
70:2545–2555, 1996).
Infection by the human herpesvirus Epstein-Barr virus
(EBV) occurs in most individuals. EBV is the causative agent
of infectious mononucleosis and is associated with a variety of
malignant disorders, including Burkitt’s lymphoma and naso-
pharyngeal carcinoma (38, 52). EBV infects both B lympho-
cytes and epithelial cells. Upon infection of epithelial cells, the
virus enters the lytic cycle, where it actively replicates and
produces new virus particles (52). In contrast, infection of B
lymphocytes usually results in a latent state of infection, with
the virus expressing only a small subset of genes (52). The EBV
immediate-early proteins, BZLF1 and BRLF1, are able to
disrupt latency in EBV-infected cells and initiate lytic viral
replication (3, 6, 51, 53, 61, 69).
During productive EBV infection, expression of BRLF1 and
BZLF1 occurs simultaneously within the cell (38). Both
BZLF1 and BRLF1 are transcriptional activators of early EBV
genes. BZLF1 binds to Ap-1-like sequences, while BRLF1
binds directly to a GC-rich motif (13, 19, 20, 22, 37). BZLF1
and/or BRLF1 binding sites are present upstream of most early
EBV promoters (7, 15, 23, 31, 43, 50, 64). BRLF1 also activates
the transcription of several other genes, including the EBV
DNA polymerase and c-myc genes, through an indirect mech-
anism (16, 21). Both the viral polymerase and c-myc genes have
upstream E2F binding sites (27, 44); the E2F site in the viral
polymerase promoter is required for BRLF1 activation of this
promoter (44), suggesting that BRLF1 may activate certain
genes through modulation of E2F1.
Frequently, viruses encode regulatory proteins which mod-
ulate cell cycle progression within the infected cell. The smaller
DNA tumor viruses (adenovirus, papillomavirus, and papova-
viruses) all encode regulatory proteins (E1A, E7, and T anti-
gen, respectively) (9, 11, 67) which interact with and inhibit
retinoblastoma (Rb) function. Each of these viruses likewise
encodes a protein (E1B, E6, and T antigen, respectively) which
inhibits p53 function (40, 42, 55, 66). Inhibition of Rb and p53
function leads to S phase induction, thereby promoting maxi-
mally efficient replication of these viruses.
In herpesviruses, lytic viral replication is associated with a
block in cell cycle progression rather than with induction of S
phase (2, 8, 33, 45, 56). Nevertheless, the immediate-early
proteins of both cytomegalovirus (CMV) and EBV inhibit Rb
and p53 function (17, 47, 68, 70). In addition, both herpes
simplex virus and CMV modulate E2F function(s) (28, 48, 49).
Thus, efficient herpesvirus replication probably requires the
regulation of critical cell cycle proteins.
The BRLF1 protein was recently shown to interact directly
with Rb (68), but its effect on cell cycle progression is un-
known. We have used a BRLF1-expressing adenovirus to ex-
amine the effect of BRLF1 on a variety of cell cycle regulatory
proteins. We show that BRLF1 expression is sufficient to in-
duce contact-inhibited, quiescent human fibroblasts to enter S
phase and dramatically increases the level of E2F1. Consistent
with the increased levels of E2F1, BRLF1-expressing cells have
increased levels of p53 and p21 and rapidly die by apoptosis.
BRLF1 expression is also associated with decreased levels of
Rb, p107, and p130. Thus, in addition to its role as a transcrip-
tional activator, the EBV immediate-early protein BRLF1 has
profound effects on key cell cycle regulatory proteins.
MATERIALS AND METHODS
Cell culture. A secondary culture of normal human fibroblasts (NHF5-neo,
referred to here as NHF [4, 36]) was derived from neonatal foreskin. The
fibroblasts were maintained in Eagle’s minimal essential medium, supplemented
with 10% fetal bovine serum (FBS) and nonessential amino acids. U-2 OS
(ATCC HTB 96) and Saos-2 (ATCC HTB 85), both human osteosarcoma cell
lines, were maintained in McCoy’s 5a medium supplemented with 15% FBS.
HeLa, a human cervical carcinoma cell line, and NPC-KT, an EBV-positive
nasopharyngeal carcinoma fusion cell line (63), were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 5% FBS. 293, a transformed pri-
mary human embryonal kidney cell line expressing the transforming genes of
adenovirus type 5 (18), was maintained in Dulbecco’s modified Eagle’s medium
* Corresponding author. Mailing address: Lineberger Comprehen-
sive Cancer Center, University of North Carolina, Chapel Hill, NC
27599. Phone: (919) 966-1248. Fax: (919) 966-8212. E-mail: shann
@med.unc.edu.
6540
supplemented with 10% FBS. B95-8, an EBV-infected marmoset B-cell line, was
maintained in RPMI medium supplemented with 10% FBS. All media contained
penicillin (100 U/ml) and streptomycin (100 mg/ml). The cells were maintained
at 37°C in a humidified atmosphere containing 10% CO2. To induce B95-8 cells
into lytic EBV infection, TPA (12-O-tetradecanoylphorbol-13-acetate; 30 ng/ml)
and sodium butyrate (5 mM) were added to the culture medium 72 h prior to
harvest.
Plasmid DNAs and adenovirus vectors. E2F1 pcDNA3, which was kindly
provided by Joseph Nevins, contains the human E2F1 cDNA in the pcDNA3
vector (Invitrogen). pRTS 15, kindly provided by Diane Hayward, contains a
genomic BRLF1 fragment expressed by the simian virus 40 (SV40) promoter in
the pSG5 vector (Stratagene).
The BRLF1 recombinant adenovirus (AdBRLF1) was constructed by cloning
the 2,188-bp DraI-XbaI fragment from pEBV-RIE (31), containing the BRLF1
gene, into the adenovirus shuttle vector pAdLox (24). The AdBRLF1 recombi-
nant adenovirus was produced by cre-lox-mediated recombination of the
pAdLox-BRLF1 vector with a replication-deficient, E1- and E3-deleted type 5
adenovirus. BRLF1 gene expression is driven by the CMV immediate-early
promoter in AdBRLF1. The control adenovirus, AdLacZ, is identical to
AdBRLF1, except that it contains the bacterial b-galactosidase gene rather than
BRLF1. AdBRLF1 and AdLacZ adenovirus stocks were generated in 293 cells
and prepared by the Gene Therapy Core Facility, University of North Carolina.
Adenovirus infections. Normal human fibroblasts (NHF) (106) were plated on
60-mm plates and U-2 OS, Saos-2, HeLa, and 293 cells (106) were plated on
100-mm plates 24 h prior to infection. The normal growth medium was removed
and replaced with adenovirus in 2% FBS in the appropriate media; a multiplicity
of infection (MOI) of 500 was used for NHF, while an MOI of 50 was used for
U-2 OS, Saos-2, HeLa, and 293 cells. The cells were infected in a small volume
for 2 to 3 h; fresh medium containing serum was then added to the infection
media to return the serum concentration to that used in the normal growth
media for each cell type.
Transfections. Plasmid DNA was purified with the Qiagen Maxi kit as speci-
fied by the manufacturer. DNA was transfected by electroporation with 5 mg of
DNA and 107 cells per condition. The cells were shocked at 1,500 V with a
Zapper electroporation unit (Medical Electronics Shop, University of Wisconsin,
Madison, Wis.). Epithelial cells were harvested and suspended in RPMI medium
supplemented with 10% FBS prior to electroporation. Protein extracts were
harvested 48 h posttransfection.
Cell cycle analysis. Cells were incubated with 10 mM bromodeoxyuridine
(BrdU) for 60 min at 37°C, 24 or 48 h after infection with adenovirus. Trypsin-
released cells were fixed in 1.5 ml of cold 13 phosphate-buffered saline (PBS)–3
ml of ice-cold 95% ethanol and incubated at 4°C overnight. The cells were
pelleted, suspended in 3 ml of 0.8% pepsin in 0.1 N HCl, and incubated at 37°C
for 20 min. Lysates were centrifuged, nuclear pellets were suspended in 1.5 ml of
2 N HCl and incubated at 37°C for 20 min, 3 ml of 0.1 M sodium borate was
added, and the lysates were repelleted. The nuclear pellets were washed in IFA
(10 mM HEPES [pH 7.4], 150 mM NaCl, 4% FBS, 0.1% sodium azide) contain-
ing 0.5% Tween 20. They were then stained with anti-BrdU antibody (1:50;
Becton Dickinson) in IFA at room temperature (RT) for 30 min, washed with
IFA containing Tween 20, counterstained with goat anti-mouse immunoglobulin
G (whole molecule)-fluorescein isothiocyanate conjugate (1:100; Sigma) in IFA
at RT for 30 min, and washed with IFA containing Tween 20. Nuclear pellets
were suspended in IFA containing 500 mg of RNase A and 50 mg of propidium
iodide per ml and incubated at 37°C for 15 min and then on ice overnight.
Fluorescence was measured with a fluorescence-activated cell sorter (FACS;
Becton Dickinson).
Immunofluorescence. Cells were harvested 24 h postinfection, washed with
PBS, fixed in 60% acetone on ice for 10 min, and washed with PBS–0.5% bovine
serum albumin (BSA). They were then stained with anti-BRLF1 antibody (1:100;
Argene) in PBS–0.5% BSA for 60 min and washed with PBS–0.5% BSA and
counterstained with goat anti-mouse immunoglobulin G (whole molecule)-fluo-
rescein isothiocyanate conjugate (1:100) in PBS–0.5% BSA for 60 min. They
were then washed and suspended in PBS and analyzed with a FACS.
Apoptosis assays. Apoptosis was determined by three methods: Hoechst stain-
ing, a DNA fragmentation assay (39, 54) and immunoblotting. In Hoechst stain-
ing, the cells were fixed in methanol-acetic acid (3:1) for 2 h, stained with
Hoechst stain for 10 min, and viewed by fluorescence microscopy for apoptotic
bodies. In DNA fragmentation analysis for HeLa cells, the cells were pelleted
and rinsed in PBS and then suspended in 0.5 ml of DNA extraction buffer (20
mM Tris HCl [pH 7.4], 10 mM EDTA, 0.2% Triton X 100) and incubated at RT
for 10 min. Debris was pelleted, and supernatant was transferred to a new tube
and treated with proteinase K (100 mg/ml) at 50°C overnight. Samples were
treated with RNase A (50 mg/ml) at 37°C for 2 h. DNA was extracted twice with
phenol and once with an isoamyl alcohol-chloroform (1:24) mixture and precip-
itated with 2 volumes 95% ethanol–1/10 volume of 10 M ammonium acetate–
glycogen (5 mg/ml) at 220°C overnight. The DNA was pelleted, suspended in 13
TE (10 mM Tris [pH 7.5], 1 mM EDTA), and electrophoresed on a 1.25%
agarose gel. In DNA fragmentation analysis for normal human fibroblasts, float-
ing cells were pelleted, washed in PBS, suspended in 40 ml of PBS–360 ml of lysis
buffer (10 mM Tris [pH 7.5], 10 mM EDTA [pH 8], 0.6% sodium dodecyl
sulfate), and incubated at 37°C for 2 h. Then 100 ml of 5 M NaCl was added to
each sample, and the mixture was incubated at 4°C overnight. Samples were
centrifuged to remove cell debris, and DNA was precipitated with 2 volumes of
cold 95% ethanol overnight at 220°C. The DNA was pelleted, washed with 70%
ethanol, suspended in 13 TE, and analyzed on a 1.25% agarose gel. Lastly,
apoptosis was monitored by immunoblotting for poly(ADP-ribose) polymerase
(PARP) cleavage (41) as described below.
Immunoblotting. Cells were harvested 24 to 48 h postinfection and washed
with PBS, and nuclear extracts were obtained as previously described (10).
Proteins were separated by polyacrylamide gel electrophoresis and blotted onto
a nitrocellulose membrane. The membranes were washed with blotting buffer
(13 PBS, 0.05% Tween 20, 1% milk) and incubated at RT for 60 min with
primary antibody in blotting buffer. Primary antibodies included anti-BMRF1
(1:40; Capricorn Products, Inc.), anti-E2F1 (1:100; C-20 sc-193 [Santa Cruz]),
anti-E2F4 (1:1,000; C-108 sc-512X [Santa Cruz]), anti-Rb (1:250; 14001A G3-245
[PharMingen]), anti-p107 (1:1,000; C-18 sc-318X [Santa Cruz]), anti-p130 (1:
1,000; C-20 sc-317X [Santa Cruz]), anti-p53 (1:200; DO-1 sc-126 [Santa Cruz]),
anti-p21 (1:500; C-19 sc-397 [Santa Cruz]), and anti-PARP (1:100; A-20 sc-1562
[Santa Cruz]). The membranes were washed in blotting buffer and incubated
with horseradish peroxidase-conjugated secondary antibody at RT for 60 min.
The membranes were washed in blotting buffer, and proteins were detected by
enhanced chemiluminescence (ECL; Amersham).
Viral DNA replication assay. Viral DNA was isolated at various times postin-
fection (0, 24, and 48 h) by the method of Hirt (29). Extracts were treated with
DNase-free proteinase K prior to extraction, ethanol precipitation, and suspen-
sion in 13 TE. Viral DNA was digested with ClaI and electrophoresed on a 0.8%
agarose–Tris-borate-EDTA (TBE) gel. The DNA was transferred to a nitrocel-
lulose membrane by the method of Southern (57). The immobilized DNA was
detected with a 32P-labeled pAdlox DNA probe and visualized by autoradiogra-
phy.
Electrophoretic mobility shift assay. Nuclear extracts (12 mg) were incubated
at RT for 30 min in a 20-ml reaction volume in 20 mM HEPES (pH 7.9)–20%
glycerol–0.1 M KCl–0.2 mM EDTA–0.5 mM dithiothreitol supplemented with 20
mg of BSA and 2 mg of denatured salmon sperm DNA. When applicable,
competing antibodies (1 ml of E2F1 [Santa Cruz]) or DNA (2 pmol of cyclic
AMP-responsive element binding protein [CREB; Promega] or E2F [a 24-bp
oligonucleotide containing the E2F binding site from the dihydrofolate reductase
promoter; 59 CCACAATTTCGCGCCAAACTTGAC 39]) was added to the
nuclear extracts prior to the 20-min incubation. A radiolabeled E2 oligonucleo-
tide probe (2 3 104 cpm) spanning nucleotides 231 to 274 of the adenovirus E2
promoter (32) was added to each sample, and the mixtures were incubated at RT
for 20 min. A 2-ml volume of 1.53 loading dye (glycerol; 13 TE [1:1]) was added
to each sample, and the mixtures were electrophoresed on a 4.5% polyacryl-
amide–0.11% bisacrylamide gel in 0.53 TBE at 4°C. The gel was dried, and
complexes were visualized by autoradiography.
RESULTS
AdBRLF1 induces lytic EBV infection. A recombinant ade-
novirus, AdBRLF1, was constructed to express BRLF1 in a
majority of cells for these studies. The recombinant adenovirus
(in which BRLF1 is driven by the CMV IE promoter) has E1
and E3 deleted and therefore is replication deficient (Fig. 1A).
To confirm the expression of functional BRLF1 protein from
AdBRLF1, NPC-KT cells (which harbor latent EBV) were
either mock infected or infected with the control AdLacZ
vector or AdBRLF1 and assayed for expression of an early
EBV protein, BMRF1, used as an index of viral replication.
Immunoblot analysis indicated that neither mock-infected nor
AdLacZ-infected cells expressed the BMRF1 protein. How-
ever, AdBRLF1 was able to induce lytic EBV infection, as
indicated by the expression of BMRF1 (Fig. 1B). These results
confirm that the AdBRLF1 vector produces functional BRLF1
protein.
The infection efficiency of AdBRLF1 was analyzed by FACS
analysis (with a BRLF1-specific monoclonal antibody) in a
variety of cell types. As shown in Fig. 1C, approximately 90%
of U-2 OS cells expressed the BRLF1 protein when infected
with an MOI of 50. Similar results were obtained in experi-
ments with HeLa and Saos-2 cells (data not shown); however,
an MOI of 500 was required to infect a similar percentage of
NHF. To confirm that AdBRLF1 expresses a level of BRLF1
which is similar to that found in cells lytically infected with
EBV, FACS analysis was used to compare the level of BRLF1
expression in AdBRLF1-infected fibroblasts and lytically in-
fected B95-8 cells (Fig. 1D). Although only 10% of B95-8 cells
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FIG. 1. The AdBRLF1 recombinant adenovirus efficiently infects cells. (A) Schematic representation of the recombinant adenovirus expressing BRLF1
(AdBRLF1). AdBRLF1 was produced by cre-loxP-mediated recombination of the pAdLox-BRLF1 shuttle vector with a replication-deficient, E1- and E3-deleted type
5 adenovirus (24). ITR, inverted terminal repeat, c, packaging signal. (B) NPC-KT cells (with a latent EBV infection) were mock, AdLacZ, or AdBRLF1 infected at
an MOI of 50 and immunoblotted 24 h after infection by using a monoclonal antibody directed against the early lytic EBV protein BMRF1. (C) U-2 OS cells were
infected with AdLacZ (left) or AdBRLF1 (middle) (MOI, 50) and analyzed for BRLF1 expression by immunofluorescence staining and FACS analysis 24 h after
infection. The right panel represents an overlay of the AdLacZ and AdBRLF1 histograms; cells within the R1 bracket were considered positive for BRLF1 expression.
(D) NHF, either AdLacZ or AdBRLF1 infected (MOI, 500), were analyzed for BRLF1 expression 24 h postinfection. In a parallel experiment, B95-8 cells, in the
presence (1) or absence (2) of the inducing agent, TPA, were also examined for BRLF1 expression. The R1 bracket indicates cells which were considered positive
for BRLF1 expression.
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expressed BRLF1 in this experiment upon TPA induction,
while 78% of the fibroblasts expressed BRLF1, the level of
BRLF1 expression per cell in B95-8 cells was similar to or
slightly higher than the level observed in AdBRLF1-infected
fibroblasts. The mean fluorescence units of the BRLF1-ex-
pressing population in induced B95-8 cells and AdBRLF1-
infected fibroblasts were 587 and 143, respectively (Fig. 1D).
These experiments indicate that the level of BRLF1 expression
induced by AdBRLF1 infection is biologically relevant and
that the efficiency of AdBRLF1 infection in the above cell lines
is sufficient to examine the effect of BRLF1 on cell cycle pro-
gression.
AdBRLF1 induces cells to enter S phase. To determine the
effect of BRLF1 on cell cycle progression, cells were either
mock infected or infected with the control AdLacZ virus or the
AdBRLF1 virus and were labeled with BrdU for 60 min 1 or 2
days after infection to determine the percentage of cells in S
phase. BrdU incorporation was quantitated by using a BrdU-
specific antibody in FACS analysis. As shown in two indepen-
dent experiments (Table 1), AdBRLF1-infected confluent U-2
OS and NHF cultures had many more cells in S phase than did
the mock-infected or AdLacZ-infected cultures. In confluent
U-2 OS cultures, 70 to 75% of AdBRLF1-infected cells were in
S phase, versus only 32 to 45% of cells infected with the control
adenovirus vector. More strikingly, AdBRLF1 was able to
overcome the G0 block imposed by contact inhibition in the
NHF, with the percentage of cells in S phase increasing from 7
to 32% following BRLF1 expression; similar results were ob-
tained in a second independent experiment (Table 1). In con-
trast to the results found with U-2 OS osteosarcoma cells
(which have wild-type p53 and Rb), no increase in the percent-
age of cells in S phase was evident after AdBRLF1 expression
in the Saos-2 osteosarcoma cell line (which has no Rb or p53).
These results indicate that BRLF1 is able to induce S phase
entry, possibly in a p53- and/or Rb-dependent manner.
To further examine the effect of BRLF1 expression on the
cell cycle, AdBRLF1-infected cells were stained with pro-
pidium iodide after BrdU labeling and analyzed by FACS.
Cell cycle profiles of mock-infected, AdLacZ-infected, and
AdBRLF1-infected cells 24 h postinfection are shown in Fig.
2A and B. The DNA content is represented on the x axis, and
BrdU fluorescence is represented on the y axis. Cells which are
entering or in S phase incorporate BrdU and are represented
in the box labeled S. As suggested by the previous experiments,
BRLF1 expression in NHF (Fig. 2A) and U-2 OS cells (Fig.
2B) increased the number of cells in S phase. Interestingly,
contact-inhibited BRLF1-expressing NHF which had become
detached from the plate (Fig. 2C, AdBRLF1 nonadherent)
exhibited an even greater percentage of cells in S phase. In
contrast, BRLF1 did not increase S phase progression in
Saos-2 cells (data not shown).
Although BRLF1 increased the total number of diploid fi-
broblasts in early S phase, the number of diploid fibroblasts in
mid-S phase did not increase, even after 48 h, suggesting that
BRLF1 may induce a block in S phase progression (Fig. 2A
and B). To confirm that the increase in the number of S phase
cells evident in BRLF1-expressing cells was due to cellular
DNA replication and not adenovirus DNA replication, we
performed a viral DNA replication assay with NHF and 293
cells (Fig. 2D). As expected, in the presence of adenovirus
E1A protein, adenovirus DNA replication occurred for both
AdLacZ and AdBRLF1 in 293 cells (Fig. 2D, lanes 8 to 12).
However, essentially no viral DNA replication was evident in
AdLacZ- or AdBRLF1-infected NHF (lanes 1 to 7). Further-
more, BRLF1-infected NHF treated with hydroxyurea, an in-
hibitor of semiconservative DNA replication but not of DNA
repair synthesis (5), exhibited diminished BrdU incorporation
per cell (data not shown). These results support the conclusion
that the increase in the number of S phase cells evident for
BRLF1-infected NHF is due to cellular DNA replication.
AdBRLF1 induces an increase in E2F1. Entry into S phase
is controlled, in part, by the level of transcriptionally active
E2F (34, 39, 65). Therefore, the effect of BRLF1 expression on
two different E2F family members was examined (Fig. 3A).
Infection with the AdBRLF1 vector dramatically increased the
level of E2F1 in NHF, HeLa and U-2 OS cells. However,
consistent with the cell cycle results, BRLF1 expression did not
increase E2F1 level in Saos-2 cells. In contrast to its effect on
E2F1, BRLF1 did not increase the level of E2F4 in any cell
type (Fig. 3A).
To determine whether the BRLF1-induced increase in E2F1
occurs only within the context of the adenovirus system, HeLa
cells were transfected with a BRLF1 expression plasmid, pRTS
15, or a control vector and assayed for E2F1 expression (Fig.
3B). A small increase in the E2F1 level was evident in the
BRLF1-transfected cells compared to the control vector (Fig.
3B, lanes 1 and 2). Although the increase in the E2F1 level was
much less dramatic in the BRLF1-transfected cells (lanes 1 and
2) than that seen in AdBRLF1-infected cells (Fig. 3A, lanes 3
and 4), the level of BRLF1 expression by the transfected plas-
mid was much less than that by the AdBRLF1 vector (Fig. 3B,
lanes 4 and 5). These results indicate that BRLF1 is capable of
inducing E2F1 in both transfection and recombinant adenovi-
rus environments.
BRLF1 reduces the level of Rb, p107, and p130. Since
BRLF1 has previously been shown to interact directly with Rb
(68), we also examined the effect of BRLF1 expression on the
level of Rb, p107, and p130. Interaction between a number of
viral proteins (including BK virus and SV40 T antigens and
papillomavirus E7) and Rb family members has been shown to
diminish the overall protein levels of Rb family members (25,
35, 58, 59). As shown in Fig. 4, AdBRLF1-infected NHF and
U-2 OS cells had a decreased level of Rb, p107, and p130 in
comparison to AdLacZ-infected cells. Thus, the ability of
BRLF1 to induce S phase progression may reflect not only
increased levels of E2F1 but also decreased levels of Rb family
members.
AdBRLF1 induces increased levels of free E2F. S phase
progression is mediated by free E2F (not bound to Rb family
members) (34, 39, 65). An electrophoretic mobility shift assay
was performed to compare the E2F DNA binding activity of
NHF which were either mock infected, AdLacZ infected, or
AdBRLF1 infected (Fig. 5, lanes 1 to 3). Addition of an E2F
DNA competitor demonstrated that the majority of the DNA
complexes contain E2F (lanes 5 and 8). Preliminary experi-
ments involving deoxycholate treatment and a variety of anti-
bodies directed against Rb, p107, p130, E2F1, and E2F4 were
performed to identify the positions of free E2F and various
TABLE 1. BRLF1 activates S phase progression
Infection
% of S phase cellsa
NHF U-2 OS Saos-2
Expt 1 Expt 2 Expt 1 Expt 2 Expt 1 Expt 2
Mock 4 3 44 55 39 44
AdLacZ 7 2 32 45 44 46
AdBRLF1 32 36 75 70 35 48
a Percentage of S phase cells as determined by BrdU incorporation. Results
are shown for two independent experiments.
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FIG. 2. Cell cycle analysis of AdBRLF1-infected cells. (A) NHF were mock, AdLacZ, or AdBRLF1 infected. Prior to harvest, the cells were labeled for 1 h with
BrdU, stained with propidium iodide and an anti-BrdU antibody, and then subjected to FACS analysis. The DNA content (propidium iodide staining) is represented
on the x axis, and BrdU fluorescence is represented on the y axis. An AdLacZ-infected control, not labeled with BrdU, was included to determine the background
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E2F complexes (data not shown). Mock-infected or AdLacZ-
infected NHF had predominantly E2F4-composed complexes
(data not shown). In AdBRLF1-infected cells, there was an
increase in the level of free E2F, and this increase was due to
E2F1 (Fig. 5, lanes 3 and 9). Although it was not always
possible to differentiate between Rb-E2F and p107-E2F com-
plexes, in most experiments there was a decrease in the level of
the mixed Rb-E2F and p107-E2F complexes. These results
indicate that BRLF1 increases the level of free E2F1 in cells,
consistent with its ability to increase the total level of E2F1
while decreasing the level of Rb.
AdBRLF1 induces apoptosis. In spite of the ability of
BRLF1 to induce S phase progression, AdBRLF1-infected
cells died within 3 days after infection (data not shown). Pro-
pidium iodide staining of AdBRLF1-infected cells showed a
large number of cells containing less than 13 DNA, suggesting
that BRLF1-induced cell death is due to apoptosis (data not
shown; such cells are excluded from the cell cycle analysis in
Fig. 2). Hoechst staining of BRLF1-infected NHF, HeLa and
U-2 OS cells revealed more apoptotic bodies (Fig. 6A) than in
AdLacZ-infected cells (data not shown). To further study
BRLF1-induced apoptosis, we analyzed DNA fragmentation
in NHF released into the supernatant at various times postin-
fection. This method was previously used to demonstrate that
E2F-1 expression induces apoptosis in rat fibroblasts (39). As
fluorescence for each cell type. The locations of the G0/G1, G2/M, and S phases
are indicated. The apparent increased fraction of 4N S phase cells in BRLF1-
infected cells probably reflects S phase initiation by tetraploid fibroblasts (14).
(B) U-2 OS cells were infected with the various adenoviruses and analyzed as in
panel A. (C) NHF were mock, AdLacZ or AdBRLF1 infected, stained with
propidium iodide, and subjected to FACS analysis; adherent and nonadherent
AdBRLF1-infected cells were analyzed separately. DNA content is represented
on the x axis, and cell number is represented on the y axis. (D) NHF (lanes 1 to
7) and 293 cells (lanes 8 to 12) were infected with AdLacZ or AdBRLF1, and
viral DNA was harvested at various times postinfection (0, 24, and 48 h) by the
Hirt method (29). DNA was digested, separated by electrophoresis, and detected
with a linearized 32P-labeled pAdLox probe. Samples were visualized by auto-
radiography. The bands representing replicated BRLF1 and AdLacZ adenovirus
DNA are indicated on the right.
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shown in Fig. 6B, AdBRLF1-infected NHF had fragmented
DNA similar to that produced by the apoptotic drug stauro-
sporine in these cells (lanes 9 to 11). AdBRLF1 expression also
induced apoptosis in HeLa cells as evidenced by DNA frag-
mentation and laddering (Fig. 6B) and in U-2 OS cells as
evidenced by PARP cleavage (Fig. 6C). These results indicate
that BRLF1 induces apoptosis in at least some cell types.
E2F1 induces apoptosis by activating p53 (39). Similarly,
BRLF1 (by inducing E2F1) might be expected to increase the
level of p53. As shown in Fig. 6D, this is indeed the case. The
p53 induced by BRLF1 appears to be functional, since BRLF1
expression is also associated with increased p21 (which is tran-
scriptionally activated by p53) (12). The findings that BRLF1
induces p53 and that apoptosis is reduced in p53-deficient
Saos-2 cells, suggests that BRLF1-induced apoptosis is at least
partially mediated through p53.
DISCUSSION
BRLF1 plays a critical role in EBV regulation, since its
expression is sufficient to induce the switch from latent to lytic
FIG. 3. BRLF1 induces an increase in E2F1 protein. (A) HeLa, U-2 OS, Saos-2, and NHF cells were mock, AdLacZ, or AdBRLF1 infected or transfected with
5 mg of the E2F1 expression vector E2F1 pcDNA3 (HeLa cells only) and analyzed for E2F1 and E2F4 expression by immunoblotting. (B) HeLa cells were transfected
(5 mg) with the control vector pSG5 or the BRLF1-expression vector pRTS 15 and analyzed for E2F1 expression by immunoblotting (left). The level of BRLF1
expression in HeLa cells infected with AdBRLF1 or transfected with the pRTS 15 expression vector was determined by immunoblotting (right).
FIG. 4. BRLF1 decreases the level of Rb family members. NHF and U-2 OS
cells were mock, AdLacZ, or AdBRLF1 infected and analyzed for the level of
Rb, p107, and p130 at 24 h postinfection.
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infection (51, 69). As is the case for other critical viral regula-
tory proteins, such as SV40 T antigen and adenovirus E1A,
BRLF1 may also regulate the cell through multiple different
mechanisms, thereby creating the most hospitable environ-
ment for lytic viral replication. Here we demonstrate that
BRLF1 dramatically increases the level of cellular E2F1 while
simultaneously decreasing the expression of Rb family mem-
bers. The induction of E2F1 is accompanied by S phase entry
and subsequent apoptosis. Thus, in addition to its ability to
activate early EBV genes through a direct DNA binding mech-
anism, BRLF1 profoundly affects the host cell environment.
Although BRLF1 has been recently shown to interact di-
rectly with Rb (68), the functional consequences of this inter-
action have not been well studied. Our results show an overall
reduction in the level of Rb family members in BRLF1-ex-
pressing cells. Although it has been suggested that the Rb-
BRLF1 interaction may act to disrupt the Rb-E2F1 complex
(68), a major consequence of the BRLF1-Rb interaction may
instead be to reduce the stability of Rb family members. Sim-
ilar results have recently been reported with other viral pro-
teins (including SV40 T antigen, BK virus T antigen, and pap-
illomavirus E7) which interact directly with Rb (25, 35, 58, 59).
Somewhat surprisingly, the most dramatic effect of BRLF1
expression is the induction of E2F1. In fact, the BRLF1-in-
duced activation of S phase entry may be due primarily to
E2F1 induction rather than to inactivation of Rb. As previously
observed with E2F1 expression (39), BRLF1 is likewise strik-
ing in its ability to override signals of quiescence in NHF. Like
E2F1, BRLF1 also induces massive apoptosis (39). Consistent
with the ability of BRLF1 to increase the level of total cellular
E2F1, we also observed an increase in the level of free E2F1
binding activity. Thus, activation of E2F1 (perhaps in conjunc-
tion with the loss of Rb activity) is probably responsible for
much of the phenotype observed in AdBRLF1-infected cells.
Interestingly, the CMV IE protein IE-72 was also recently
shown to activate E2F1 function, in this case through direct
phosphorylation (46, 48), and herpes simplex virus infection
results in increased levels of free E2F as well as of E2F-p107
complexes (28). Thus, modulation of E2F function by IE pro-
teins may be a requirement for efficient lytic replication of
herpesviruses.
Lytic EBV infection occurs in postmitotic, differentiated ep-
ithelial cells (52), which presumably have little if any free E2F.
However, it has already been shown that an E2F site is essen-
tial for BRLF1 activation of the EBV DNA polymerase (44),
suggesting that free cellular E2F is required for replication of
viral DNA. Consistent with this model, the level of E2F1 is
increased during induction of lytic EBV infection in Akata
cells (68). In addition to activating the EBV polymerase, E2F1
induction would be expected to activate the transcription of
many proteins involved in cellular DNA synthesis and cell cycle
progression. E2F-induced cellular proteins (which would nor-
mally be expressed at the late G1/S interphase) may be re-
FIG. 5. BRLF1 increases free E2F1 levels. NHF were mock, AdLacZ, or AdBRLF1 infected. Nuclear extracts were harvested at 24 h postinfection and analyzed
for DNA binding to a labeled probe containing an E2F binding site by the electrophoretic mobility shift assay (lanes 1 to 3). DNA competitors (CREB [lanes 4 and
7] and E2F [lanes 5 and 8]) and competing E2F1 antibody (lanes 6 and 9) were included in the binding-reaction mixture to determine the composition of various DNA
binding complexes. The positions of free E2F, E2F complexes, and supershifted E2F1 are indicated. The decrease in the level of the uppermost E2F complex evident
in the AdLacZ sample was unusual; these complexes were typically visible for this sample.
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FIG. 6. BRLF1 induces apoptosis. (A) NHF, HeLa, and U-2 OS cells were infected with AdBRLF1. The cells were fixed in methanol-acetic acid (3:1) for 2 h, stained
with Hoechst stain for 10 min, and visualized by fluorescence microscopy. Apoptotic cells are indicated by the arrows. (B) NHF and HeLa cells were mock, AdLacZ,
and AdBRLF1 infected. Apoptosis in HeLa cells was measured 2 days after infection, while apoptosis in NHF was examined on days 1, 2, and 3 postinfection by using
a DNA ladder assay (39, 54). Staurosporine-treated cells served as the positive control in both assays. DNA size markers (in kilobases) are indicated on the right of
the NHF lanes. (C) U-2 OS cells were mock, AdLacZ, or AdBRLF1 infected and analyzed for PARP cleavage by immunoblotting. (D) NHF were mock, AdLacZ, or
AdBRLF1 infected, and the levels of p53 and p21 were determined by immunoblotting 24 h postinfection.
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quired for efficient lytic EBV replication in differentiated ep-
ithelial cells.
Currently, we are not certain how BRLF1 induces E2F1
levels. Although BRLF1 is a transcriptional activator, we have
not found that AdBRLF1 infection in NHF increases the level
of E2F1 mRNA (60). Therefore, BRLF1 more probably in-
creases the stability of E2F1 protein. Ubiquitination of E2F1
targets it for degradation by the proteosome pathway; since the
interaction between Rb and E2F1 protects E2F1 from degra-
dation (1, 30), the decreased level of Rb in AdBRLF1-infected
cells might have been expected to lower E2F1 levels. It will be
important to determine if BRLF1 can interact directly with
E2F1 (preventing degradation) or if it stabilizes the Rb-E2F
interaction. In support of the latter hypothesis, we did not
observe an BRLF1-induced increase in E2F1 level in Saos-2
cells, the only cell line studied which is lacking Rb. We cannot
absolutely exclude the possibility that an adenovirus-encoded
protein collaborates with BRLF1 to increase E2F1 levels, since
the increase was much more dramatic in cells infected with the
AdBRLF1 vector than in BRLF1-transfected cells.
Our data suggest that BRLF1 induces apoptosis, most prob-
ably through induction of E2F1. The observed increase in the
level of p53 (and of the p53-responsive protein, p21) no doubt
reflects the cellular response to unscheduled S phase entry. In
the context of the intact virus, either BZLF1 (which we have
shown interacts directly with and inhibits the function of p53)
(70) or BHRF1 (a bcl2 homolog) (26) may act to limit BRLF1-
induced apoptosis.
Our results are somewhat paradoxical, since we show that
BRLF1 activates S phase entry and yet lytic EBV infection
occurs in the presence of agents (such as sodium butyrate)
known to inhibit S phase progression (56) and may in fact be
less efficient during S phase (62). We can reconcile this para-
dox by assuming that E2F1 induction is the primary role of
BRLF1 in this process whereas induction of S phase reflects
the absence of an additional EBV protein(s) which normally
counteracts the E2F1-induced S phase entry in EBV-infected
cells. Expression of the EBV IE protein BZLF1 (which is
expressed simultaneously with BRLF1 during disruption of
viral latency) arrests cells in G0/G1 (2). Thus, in the context of
the entire virus, BZLF1 may arrest cells in G0/G1 to prevent
cellular DNA replication, while BRLF1 may aid viral replica-
tion by E2F1 induction. Consistent with this hypothesis, our
preliminary results indicate that BZLF1 does not prevent
BRLF1-induced E2F1 accumulation (data not shown). It will
be important to determine how BZLF1 and BRLF1 interact in
cells to create and maintain a cellular environment favorable
for lytic EBV replication.
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